探索KRAS与效应蛋白相互作用的结合性和性能量景观,使用构造组合的马尔科夫状态建模和性网络建模
Sian Xiao1, Mohammed Alshahrani2, Guang Hu3,4
1Department of Chemistry, Center for Research Computing, Center for Drug Discovery, Design, and Delivery (CD4), Southern Methodist University, Dallas, Texas, USA.
Protein science : a publication of the Protein Society
|July 17, 2025
概括
致癌的KRAS突变稳定了它的活性状态,通过改变过关区域动态来增强RAF1结合. 了解这些全性机制是开发向癌症治疗的关键.
科学领域:
- 分子生物学分子生物学
- 生物物理学的生物物理.
- 计算生物学是一种计算生物学.
背景情况:
- 基尔斯顿大鼠肉瘤病毒瘤基因同源 (KRAS) 是一个关键的瘤蛋白调节细胞生长.
- 瘤性KRAS突变在癌症中很常见,但KRAS质的机制仍然不清楚.
- 了解KRAS-RAF1相互作用对于癌症治疗至关重要.
研究的目的:
- 为了研究KRAS全精菌在对瘤突变的反应中的动态和能量机制.
- 描述KRAS-RAF1相互作用的热力学驱动因素和结合热点.
- 阐明特定的KRAS突变 (G12V,G13D,Q61R) 如何影响RAF1信号传输.
主要方法:
- 微秒分子动力学模拟的微秒模拟.
- 突变扫描和具有约束力的自由能量计算.
- 动态网络建模的动态网络建模
主要成果:
- 克拉斯突变 (G12V,G13D,Q61R) 稳定了活性状态并增强了RAF1的结合.
- 突变差异调节KRAS切换区域的灵活性,影响RAF1的相互作用.
- 确定了关键的结合热点和保存的全性通路,将突变与功能变化联系起来.
- 动态网络分析揭示了一种保存的全架构,它调解了长距离相互作用.
结论:
- 瘤性KRAS突变通过稳定活性状态并改变开关区域动态来增强RAF1结合.
- 特定的突变会导致KRAS中明显的形状变化和灵活性配置.
- 该研究提供了KRAS全沟通的详细地图,这对于治疗向至关重要.
- 这些发现突显了针对突变特异性KRAS构造来治疗癌症的潜力.
关键词:
克拉斯蛋白质 (KRAS) 是一种蛋白质.一个全osteric机制的机制.具有约束力的能源.计算机模拟的计算机模拟.有效分子蛋白质的作用.整合性蛋白质建模的整合性蛋白质建模马尔科夫国家模型分子动力学分子动力学突变扫描 突变扫描 突变扫描蛋白质网络分析分析更多相关视频
15:05Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
8.8K
08:49Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
Published on: June 20, 2025
540
相关概念视频
Cooperative Allosteric Transitions
2.4K
2.4K
Ligand Binding and Linkage
4.9K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.9K
Allosteric Proteins-ATCase
5.9K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.9K
Allosteric Regulation
59.1K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
59.1K
The Two-State Receptor Model
2.4K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
2.4K
Protein-protein Interfaces
13.4K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
13.4K
